参考文献 [1]annoh L. Rush, et al. Comparative quality of life in patients randomized contemporaneously to docetaxel or abiraterone in the STAMPEDE trial. 2020 ASCO-GU. Oral presentation #GU20 [2]Sydes M, et al. Adding abiraterone...
参考文献 [1]annoh L. Rush, et al. Comparative quality of life in patients randomized contemporaneously to docetaxel or abiraterone in the STAMPEDE trial. 2020 ASCO-GU. Oral presentation #GU20 [2]Sydes M, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer...
There is more evidence at this time in the M1 setting so the confidence intervals are narrower than for M0 but one should take the overall effect from the trial; the point estimate in the M0 setting (HR = 0.75) is exactly that targeted by the protocol. However, many in the ...
The protocol can be found online [13]. The trial was registered both on clinicaltrials.gov as NCT00268476 and on controlled-trials.com as ISRCTN78818544, had the relevant regulatory and ethics approval, and all patients gave written, informed consent. 2.4. Outcome measures The trial's ...
Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial There are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for hormone-nave prostate cancer. Through a protocol amendment, this wil...
Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced or metastatic prostate cancer: evaluation of drug efficacy: a multi-arm multi-stage platform randomised controlled protocol recruiting...
Communicating to trial sites that changes might be forthcoming was started many weeks before each intermediate analysis. The potential for stopping recruitment to arms was built into the trial design; therefore, such activity did not require a formal protocol amendment. A letter was circulated to ...
To our knowledge, this is the first qualitative study of HCPs to have focused on second-line treatment sequencing; changes to practice due to the STAMPEDE and CHAARTED trial data; adverse-effects of prostate cancer treatment including muscle wastage, compromising treatment and finally prostate cancer...
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial Home > Section > Chapter James, N.D.; Sydes, M.R.; Mason, M.D.; Clarke, N.W.; Anderson, J.; Dearnaley, D....
Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial There are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for hormone-nave prostate cancer. Through a protocol amendment, this wil...